Prohibitin targeting peptide 1

Drug Profile

Prohibitin targeting peptide 1

Alternative Names: Adipotide; Prohibitin-TP01

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Ablaris Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Obesity therapies; Peptides; Peptidomimetics
  • Mechanism of Action Apoptosis stimulants; Prohibitin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)
  • 04 Jan 2012 FDA approves IND application for prohibitin targeting peptide 1 in Obesity
  • 21 Dec 2010 Preclinical trials in Obesity in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top